期刊文献+

Over-expression of small ubiquitin-like modifier proteases 1 predicts chemo-sensitivity and poor survival in non-small cell lung cancer 被引量:8

Over-expression of small ubiquitin-like modifier proteases 1 predicts chemo-sensitivity and poor survival in non-small cell lung cancer
原文传递
导出
摘要 Background Non-small cell lung cancer (NSCLC) is one of the most common malignant tumors.Despite the advances in therapy over the years,its mortality remains high.The aim of this study was to evaluate the expression of small ubiquitin-like modifier (SUMO) proteases 1 (SENP1) in NSCLC tissues and its role in the regulation of vascular endothelial growth factor (VEGF) expression.We also investigated the association between the expression level of SENP1 and the clinicopathological features and survival of the patients.Methods A SENP1 small interfering RNA (siRNA) was constructed and transfected into the NSCLC cells.VEGF gene expression was analyzed by real-time polymerase chain reaction (RT-PCR).Immunohistochemistry staining was used to assess the expression of SENP1 in 100 NSCLC patients and its association with the clinicopathological features and survival was analyzed.Results VEGF expression was significantly higher in NSCLC tissues than in normal lung tissues.Inhibition of SENP1 by siRNA was associated with decreased VEGF expression.SENP1 was over-expressed in 55 of the 100 NSCLC samples (55%) and was associated with a moderate and low histological tumor grade (3.6%,38.2%,and 58.2% in high,moderate and low differentiated tumors,respectively,P=0.046),higher T stage (10.9% in T1,and 89.1% in T2 and T3 tumor samples,P <0.001)and TNM stage (10.9% in stage Ⅰ,and 89.1% in stages Ⅱ and Ⅲ tumor samples,P <0.001).The rate of lymph node metastasis was significantly higher in the SENP1 over-expression group (76.4%) than that in the SENP1 low expression group (33.3%,P <0.001).Sixty three patients received postoperative chemotherapy,including 34 with SENP1 over-expression and 29 with SENP1 low expression.Among the 34 patients with SENP1 over-expression,22 (64.7%) patients developed recurrence or metastasis,significantly higher than those in the low expression group 27.6% (8/29) (P=0.005).Multivariate Cox regression analysis showed that lymph node metastasis (P=0.015),TNM stage (P=-0.001),and SENP1 expression level (P=0.002) were independent prognostic factors for the survival of NSCLC patients.Conclusions SENP1 may be a promising predictor of survival,a predictive factor of chemo-sensitivity for NSCLC patients,and potentially a desirable drug target for lung carcinoma target therapy. Background Non-small cell lung cancer (NSCLC) is one of the most common malignant tumors.Despite the advances in therapy over the years,its mortality remains high.The aim of this study was to evaluate the expression of small ubiquitin-like modifier (SUMO) proteases 1 (SENP1) in NSCLC tissues and its role in the regulation of vascular endothelial growth factor (VEGF) expression.We also investigated the association between the expression level of SENP1 and the clinicopathological features and survival of the patients.Methods A SENP1 small interfering RNA (siRNA) was constructed and transfected into the NSCLC cells.VEGF gene expression was analyzed by real-time polymerase chain reaction (RT-PCR).Immunohistochemistry staining was used to assess the expression of SENP1 in 100 NSCLC patients and its association with the clinicopathological features and survival was analyzed.Results VEGF expression was significantly higher in NSCLC tissues than in normal lung tissues.Inhibition of SENP1 by siRNA was associated with decreased VEGF expression.SENP1 was over-expressed in 55 of the 100 NSCLC samples (55%) and was associated with a moderate and low histological tumor grade (3.6%,38.2%,and 58.2% in high,moderate and low differentiated tumors,respectively,P=0.046),higher T stage (10.9% in T1,and 89.1% in T2 and T3 tumor samples,P <0.001)and TNM stage (10.9% in stage Ⅰ,and 89.1% in stages Ⅱ and Ⅲ tumor samples,P <0.001).The rate of lymph node metastasis was significantly higher in the SENP1 over-expression group (76.4%) than that in the SENP1 low expression group (33.3%,P <0.001).Sixty three patients received postoperative chemotherapy,including 34 with SENP1 over-expression and 29 with SENP1 low expression.Among the 34 patients with SENP1 over-expression,22 (64.7%) patients developed recurrence or metastasis,significantly higher than those in the low expression group 27.6% (8/29) (P=0.005).Multivariate Cox regression analysis showed that lymph node metastasis (P=0.015),TNM stage (P=-0.001),and SENP1 expression level (P=0.002) were independent prognostic factors for the survival of NSCLC patients.Conclusions SENP1 may be a promising predictor of survival,a predictive factor of chemo-sensitivity for NSCLC patients,and potentially a desirable drug target for lung carcinoma target therapy.
出处 《Chinese Medical Journal》 SCIE CAS CSCD 2014年第23期4060-4065,共6页 中华医学杂志(英文版)
关键词 small ubiquitin-like modifier proteases 1 (SENP1) non-small cell lung cancer PROGNOSIS neoplasm recurrence small ubiquitin-like modifier proteases 1 (SENP1) non-small cell lung cancer prognosis neoplasm recurrence
  • 相关文献

参考文献3

二级参考文献23

  • 1Erler JT, Bennewith KL, Nicolau M, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature, 2006, 440: 1222-1226.
  • 2Erler JT, Bennewith KL, Cox TR, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell, 2009, 15 : 35-44.
  • 3Postovit LM, Abbott DE, Payne SL, et al. Hypoxia/ reoxygenation: a dynamic regulator of lysyl oxidase-facilitated breast cancer migration. J Cell Biochem, 2008, 103:1369-1378.
  • 4Rodriguez C, Rodriguez-Sinovas A, Martfnez-Gonzfflez J. Lysyl oxidase as a potential therapeutic target. Drug News Perspect, 2008, 21 : 218-224.
  • 5Gao Y, Xiao Q, Ma H, et al. LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proe Natl Aead Sei U S A, 2010, 107: 18892- 18897.
  • 6Denko NC, Fontana LA, Hudson KM, et al. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene, 2003, 22:5907-5914.
  • 7Chang HY, Nuyten DS, Sneddon JB, et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Prec Natl Acad Sci U S A, 2005, 102 : 3738-3743.
  • 8Chen Y, Shi G, Xia W, et al. Identification of hypoxia-regulated proteins in head and neck cancer by proteomic and tissue array profiling. Cancer Res, 2004, 64 : 7302-7310.
  • 9Pez F, Dayan F, Durivauh J, et al. The HIF-l-inducible lysyl oxidase activates HIFT via the Akt pathway in a positive regulation loop and synergizes with HIF-1 in promoting tumor cell growth. Cancer Res, 2011,71 : 1647-1657.
  • 10Santhanam AN, Baker AR, Hegamyer G, et al. Pdcd4 repression of lysyl oxidase inhibits hypoxia-induced breast cancer cell invasion. Oncogene, 2010, 29: 3921-3932.

共引文献20

同被引文献37

引证文献8

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部